Skip to main content

Compare Stocks

Date Range: 

 Helius Medical TechnologiesFc Global RealtyNuwellisViveve MedicalReShape Lifesciences
SymbolNASDAQ:HSDTOTCMKTS:FCRENASDAQ:CHFSNASDAQ:VIVEOTCMKTS:RSLS
Price Information
Current Price$15.05$0.10$3.74$2.51$5.30
52 Week RangeBuyN/ABuyBuyBuy
MarketRank™
Overall Score1.30.51.70.90.6
Analysis Score3.30.03.50.00.0
Community Score3.32.32.73.02.5
Dividend Score0.00.00.00.00.0
Ownership Score0.00.01.70.00.0
Earnings & Valuation Score0.00.00.61.30.6
Analyst Ratings
Consensus RecommendationBuyN/ABuyBuyBuy
Consensus Price Target$20.00N/A$20.00N/AN/A
% Upside from Price Target32.89% upsideN/A434.76% upsideN/AN/A
Trade Information
Market Cap$34.87 million$38.87 million$22.58 million$25.96 million$30.22 million
Beta0.722.311.550.592.03
Average Volume111,5907,405467,3231,602,4232,604
Sales & Book Value
Annual Revenue$1.50 million$40,000.00$5.51 million$6.57 million$15.09 million
Price / Sales23.25971.794.103.952.17
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$6.64 per shareN/A$12.79 per share$23.35 per share$61.65 per share
Price / Book2.270.290.110.09
Profitability
Net Income$-9,780,000.00$-2,040,000.00$-18,110,000.00$-42,530,000.00$-74,210,000.00
EPS($12.94)N/A($279.28)($338.00)N/A
Trailing P/E RatioN/A0.00N/AN/A0.00
Forward P/E RatioN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-2,716.85%-4,265.28%-254.26%-661.57%-314.18%
Return on Equity (ROE)-328.07%-24.94%-173.61%-243.62%-186.31%
Return on Assets (ROA)-201.87%-9.42%-131.01%-139.23%-101.10%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.46%0.19%
Current Ratio1.61%0.01%6.87%4.85%0.57%
Quick Ratio1.39%0.01%5.97%3.48%0.43%
Ownership Information
Institutional Ownership PercentageN/AN/A65.06%18.16%N/A
Insider Ownership Percentage17.40%5.04%0.60%4.96%N/A
Miscellaneous
Employees19N/A664237
Shares Outstanding2.32 million389.10 million6.04 million10.34 million6.17 million
Next Earnings Date5/17/2021 (Confirmed)N/AN/A5/13/2021 (Confirmed)5/13/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
EQS-News: Obalon Therapeutics, Inc. Urges Stockholders to IMMEDIATELY Vote FOR All Proposals Related to the Merger with ReShape Lifesciences IncEQS-News: Obalon Therapeutics, Inc. Urges Stockholders to IMMEDIATELY Vote FOR All Proposals Related to the Merger with ReShape Lifesciences Inc
finanztreff.de - May 12 at 8:30 AM
PRESS RELEASE: Obalon Therapeutics, Inc. Urges Stockholders to IMMEDIATELY Vote FOR All Proposals Related to the Merger with ReShape Lifesciences IncPRESS RELEASE: Obalon Therapeutics, Inc. Urges Stockholders to IMMEDIATELY Vote FOR All Proposals Related to the Merger with ReShape Lifesciences Inc
finanztreff.de - May 12 at 8:30 AM
DGAP-News: Obalon Therapeutics, Inc. Urges Stockholders to IMMEDIATELY Vote FOR All Proposals Related to the Merger with ReShape Lifesciences IncDGAP-News: Obalon Therapeutics, Inc. Urges Stockholders to IMMEDIATELY Vote FOR All Proposals Related to the Merger with ReShape Lifesciences Inc
boersennews.de - May 12 at 8:30 AM
ReShape Lifesciences (OTCMKTS:RSLS) Stock Passes Above 200 Day Moving Average of $4.97ReShape Lifesciences (OTCMKTS:RSLS) Stock Passes Above 200 Day Moving Average of $4.97
americanbankingnews.com - May 6 at 12:48 AM
Top Reddit Penny Stocks To Buy Today? 3 To Watch Right NowTop Reddit Penny Stocks To Buy Today? 3 To Watch Right Now
entrepreneur.com - April 21 at 1:36 PM
ReShape Lifesciences Inc.: ReShape Lifesciences Announces Fourth Quarter and Full Year 2020 Financial ResultsReShape Lifesciences Inc.: ReShape Lifesciences Announces Fourth Quarter and Full Year 2020 Financial Results
finanznachrichten.de - March 10 at 7:38 PM
ReShape Lifesciences Announces Fourth Quarter and Full Year 2020 Financial ResultsReShape Lifesciences Announces Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 10 at 7:38 PM
Reshape Lifesciences to Report Fourth Quarter and Full Year 2020 Financial and Operational Results on Wednesday, March 10, 2021Reshape Lifesciences to Report Fourth Quarter and Full Year 2020 Financial and Operational Results on Wednesday, March 10, 2021
finance.yahoo.com - March 8 at 12:53 PM
Obalon Therapeutics’ stock skyrockets after announcing ReShape Lifesciences mergerObalon Therapeutics’ stock skyrockets after announcing ReShape Lifesciences merger
massdevice.com - January 20 at 8:51 PM
Obalon Therapeutics stock soars to lead all gainers on massive volume after merger with ReShapeObalon Therapeutics stock soars to lead all gainers on massive volume after merger with ReShape
morningstar.com - January 20 at 3:50 PM
These Small Caps Are Ripping On Merger AnnouncementThese Small Caps Are Ripping On Merger Announcement
baystreet.ca - January 20 at 3:50 PM
ReShape Lifesciences to Merge with Obalon Therapeutics to Expand Weight Loss Product OfferingReShape Lifesciences to Merge with Obalon Therapeutics to Expand Weight Loss Product Offering
financialbuzz.com - January 20 at 3:50 PM
Obalon Therapeutics skyrockets 568% after announcing merger with weight-loss company ReShape LifesciencesObalon Therapeutics skyrockets 568% after announcing merger with weight-loss company ReShape Lifesciences
msn.com - January 20 at 3:50 PM
Obalon Therapeutics stock soars to lead all gainers on massive volume after ReShape merger dealObalon Therapeutics stock soars to lead all gainers on massive volume after ReShape merger deal
finance.yahoo.com - January 20 at 3:50 PM
Stock Alert: Obalon Therapeutics Surges 75% On News Of Merger With ReShape LifesciencesStock Alert: Obalon Therapeutics Surges 75% On News Of Merger With ReShape Lifesciences
markets.businessinsider.com - January 20 at 9:58 AM
ReShape Lifesciences Inc. to Merge With Obalon Therapeutics, Inc. to Expand Weight Loss Product OfferingReShape Lifesciences Inc. to Merge With Obalon Therapeutics, Inc. to Expand Weight Loss Product Offering
finance.yahoo.com - January 20 at 9:58 AM
rsls.pk - Reshape Lifesciences Inc Profile | Reutersrsls.pk - Reshape Lifesciences Inc Profile | Reuters
reuters.com - November 27 at 10:45 PM
ReShape Lifesciences Announces Third Quarter 2020 Financial and Operational ResultsReShape Lifesciences Announces Third Quarter 2020 Financial and Operational Results
finance.yahoo.com - November 12 at 7:30 PM
ReShape Lifesciences to Report Third Quarter 2020 Financial and Operational Results on Thursday, November 12, 2020ReShape Lifesciences to Report Third Quarter 2020 Financial and Operational Results on Thursday, November 12, 2020
finance.yahoo.com - November 10 at 9:32 AM
First Twenty-five Healthcare Professionals Enrolled in ReShapeCare(TM), a Reimbursable, Evidence-based Virtual Weight Management ProgramFirst Twenty-five Healthcare Professionals Enrolled in ReShapeCare(TM), a Reimbursable, Evidence-based Virtual Weight Management Program
wfmz.com - September 17 at 8:28 PM
First Twenty-five Healthcare Professionals Enrolled in ReShapeCare™, a Reimbursable, Evidence-based Virtual Weight Management ProgramFirst Twenty-five Healthcare Professionals Enrolled in ReShapeCare™, a Reimbursable, Evidence-based Virtual Weight Management Program
finance.yahoo.com - September 15 at 9:33 AM
ReShape Lifesciences(TM) Announces Positive Preclinical Results for Its Investigational Diabetes Bloc-Stim Neuromodulation DeviceReShape Lifesciences(TM) Announces Positive Preclinical Results for Its Investigational Diabetes Bloc-Stim Neuromodulation Device
stockhouse.com - September 12 at 6:43 PM
ReShape Lifesciencess diabetes neuromodulation device shows encouraging effect in preclinical studiesReShape Lifesciences's diabetes neuromodulation device shows encouraging effect in preclinical studies
seekingalpha.com - September 10 at 2:29 PM
ReShape Lifesciences™ Announces Positive Preclinical Results for Its Investigational Diabetes Bloc-Stim Neuromodulation DeviceReShape Lifesciences™ Announces Positive Preclinical Results for Its Investigational Diabetes Bloc-Stim Neuromodulation Device
finance.yahoo.com - September 10 at 9:28 AM
ReShape Lifesciences slides on Q2 lossesReShape Lifesciences slides on Q2 losses
massdevice.com - August 14 at 12:25 PM
DateCompanyBrokerageAction
3/30/2021Helius Medical TechnologiesNoble FinancialInitiated Coverage
2/12/2021Helius Medical TechnologiesLADENBURG THALM/SH SHInitiated Coverage
8/12/2020Helius Medical TechnologiesOppenheimerReiterated Rating
8/9/2019Helius Medical TechnologiesBTIG ResearchReiterated Rating
11/12/2020NuwellisMaxim GroupReiterated Rating
8/28/2018NuwellisDawson JamesInitiated Coverage
1/29/2021Viveve MedicalAlliance Global PartnersInitiated Coverage
7/23/2019Viveve MedicalMizuhoDowngrade
7/23/2019Viveve MedicalRaymond JamesDowngrade
7/22/2019Viveve MedicalStifel NicolausDowngrade
1/18/2019Viveve MedicalCraig HallumSet Price Target
(Data available from 5/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.